OncoMatch/Clinical Trials/NCT06123286

Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

Is NCT06123286 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Tart Cherry and Omega 3 FA (Fish Oil) for breast cancer.

Treatment: Tart Cherry · Omega 3 FA (Fish Oil) — Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. Further, both Tart Cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addition to other health issues like insomnia. There is preliminary evidence in mouse models that when given together, these supplements may have an even greater anti-inflammatory effect than when taken separately14. Although to our knowledge, no human studies have tested this hypothesis. This study has been designed to test the hypothesis that Tart Cherry and fish oil when given in combination over a 12-week period could produce beneficial changes in joint function when compared to Tart Cherry or fish oil in isolation in an obese breast cancer population experiencing AIMSS. Secondary outcomes to be assessed include pain, functional performance, quality of life and cognition.